Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.33 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.33 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.33 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377790 | 0.86 | MAPK14 (0.42) | MAPK14MAOBPTGER1MAPKAPK2 | |
| SCHEMBL3523254 | 0.77 | MAPK14 (0.41) | MAPK14MAPK11 | |
| SCHEMBL6509277 | 0.76 | MAPK14 (0.45) | MAPK14MAPKAPK2 | |
| SCHEMBL5208575 | 0.76 | MAPK14 (0.53) | MAPK14MAPK11MAOB | |
| SCHEMBL6507019 | 0.72 | MAPK14 (0.52) | MAPK14MAPKAPK2 | |
| SCHEMBL3522025 | 0.66 | MAPK14 (0.56) | MAPK14MAPK11MAOBPTGER1 | |
| SCHEMBL4381783 | 0.66 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL4377999 | 0.66 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL3521135 | 0.66 | MAPK14 (0.44) | MAPK14MAPK11MAOB | |
| SCHEMBL5204556 | 0.66 | MAPK14 (0.47) | MAPK14MAPK11MAOBMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| CN-1968937-A | Pyrimidin-4-one derivatives and their use as P38 kinase modulators | PHARMACIA CORP (US) | 2007-05-23 | — | — | CN | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1753731-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | Pharmacia Corporation (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004087677-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885MAOB 1718/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885MAPK11 48/4885MAOB 1814/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885MAOB 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.